Vanda Pharmaceuticals Inc. 8-K Filing
Ticker: VNDA · Form: 8-K · Filed: Dec 4, 2025 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Vanda Pharmaceuticals Inc. (ticker: VNDA) to the SEC on Dec 4, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market).
How long is this filing?
Vanda Pharmaceuticals Inc.'s 8-K filing is 2 pages with approximately 453 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-12-04 16:39:04
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market
Filing Documents
- vnda-20251204.htm (8-K) — 29KB
- vnda8-k1242025exhibit991.htm (EX-99.1) — 10KB
- vandaq32019earningsca_imag.jpg (GRAPHIC) — 48KB
- 0001628280-25-055393.txt ( ) — 227KB
- vnda-20251204.xsd (EX-101.SCH) — 2KB
- vnda-20251204_lab.xml (EX-101.LAB) — 22KB
- vnda-20251204_pre.xml (EX-101.PRE) — 13KB
- vnda-20251204_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On December 4, 2025, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release announcing that the U.S. Food and Drug Administration has lifted the partial clinical hold on Vanda's drug, tradipitant, for the treatment of motion sickness. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated December 4, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 4, 2025 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary